Reducing Risks of CMV Infection in Post-transplant Patients

  • Precise monitoring: Rely on accurate detection and quantification of CMV-specific CD8+ T cells in transplant patients.

  • Sensitive detection: Designed for high-avidity binding, Dextramer® technology ensures you detect even low-abundance cell populations.

  • High signal-to-noise ratio: Each Dextramer® molecule carries multiple fluorophores that generate unambiguous signals and low background.

  • Guide therapy decisions: Robust and reproducible results from whole blood samples can be helpful to avoid unnecessary antiviral treatment.

  • For IVD use: The Dextramer® CMV Kit is available for in vitro diagnostic use in the EU and the US and includes appropriate negative controls.

Let's Talk Science

Get in Touch with our Immune Monitoring Experts

Cytomegalovirus (CMV) is a common infection with a high seroprevalence in human populations. Transplant patients are particularly susceptible to morbidity and mortality from infection because of treatment-related immunosuppression. Therefore, it is essential to monitor the CMV-specific immune status and risk of CMV reactivation in adult HSCT recipients following immunosuppression.

Immudex has developed the Dextramer® CMV Kit for in vitro diagnostic use in the EU and the US. Featuring a panel of CMV-specific Dextramer® reagents, the Dextramer® CMV Kit accurately enumerates CMV-specific CD8+ T cells in whole blood samples via flow cytometry.

"I have already recommended Immudex reagents to current and former colleagues because I am satisfied with the quality of the products and the customer support."

- Scientist, Pharmaceutical Company

Dextramer CMV Kit

Take control in CMV management

Questions? Let's Talk Science!

Get in touch with our immune monitoring experts